Posts by: Joana Fernandes, PhD

Joana Fernandes, PhD

Joana brings more than 8 years of academic research and experience as well as Scientific writing and editing to her role as a Science and Research writer. She also served as a Postdoctoral Researcher at the Center for Neuroscience and Cell Biology in Coimbra, Portugal, where she also received her PhD in Health Science and Technologies, with a specialty in Molecular and Cellular Biology.

September 7, 2017

Specific Brain Rhythms May be Biomarker for Angelman Syndrome

News

A specific frequency of brain rhythms detected in electroencephalograms (EEG), called delta oscillations, may serve as a valuable biomarker for Angelman syndrome, a new study says. According to researchers, ... Read more

September 6, 2017

Researchers Find Novel Insight into Early Neuronal Deficits Leading to Angelman Syndrome

News

Researchers from the University of Connecticut School of Medicine have turned stem cells from patients with Angelman syndrome into neurons to investigate how the disease affects these cells. The ... Read more

August 10, 2017

Roche Teaming Up with Angelman Syndrome Organizations to Create a Clinical Trial Design Model

News

Roche and representatives of parent-driven organizations are collaborating on the first part of a study whose objective is to design better clinical trials and speed up the development of ... Read more

August 2, 2017August 2, 2017

Review Highlights Role of Specific RNAs in Angelman Syndrome, Other Neurodevelopmental Disorders

News

A recent review highlights the latest findings on the role of a group of molecules called long noncoding RNAs (lncRNAs) in neurodevelopmental disorders such as Angelman syndrome. The review, ... Read more

July 17, 2017

Anavex 2-73 Reduces Angelman Syndrome Seizures in Mice, Study Reports

News

ANAVEX 2-73 significantly reduced sound-triggered seizures in mice with Angelman syndrome, according to a preclinical-trial study. Its developer, Anavex Life Sciences, reported the results at the Antiepileptic Drug Trials XIV 2017 Conference in ... Read more